[go: up one dir, main page]

AU2001289102A1 - Topical formulations for delivery of interleukin-11 - Google Patents

Topical formulations for delivery of interleukin-11

Info

Publication number
AU2001289102A1
AU2001289102A1 AU2001289102A AU8910201A AU2001289102A1 AU 2001289102 A1 AU2001289102 A1 AU 2001289102A1 AU 2001289102 A AU2001289102 A AU 2001289102A AU 8910201 A AU8910201 A AU 8910201A AU 2001289102 A1 AU2001289102 A1 AU 2001289102A1
Authority
AU
Australia
Prior art keywords
interleukin
delivery
topical formulations
topical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289102A
Inventor
Camille L. Bedrosian
James C. Keith Jr.
Paul F. Schendel
Ullrich S. Schwerschlag
Nicholas W Warne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of AU2001289102A1 publication Critical patent/AU2001289102A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001289102A 2000-09-15 2001-09-17 Topical formulations for delivery of interleukin-11 Abandoned AU2001289102A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/662,994 2000-09-15
US09/662,994 US6540993B1 (en) 1995-06-27 2000-09-15 Method of treating inflammatory bowel disease using a topical formulation of IL-11
PCT/US2001/028886 WO2002022156A2 (en) 2000-09-15 2001-09-17 Topical formulations for delivery of interleukin-11

Publications (1)

Publication Number Publication Date
AU2001289102A1 true AU2001289102A1 (en) 2002-03-26

Family

ID=24660067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289102A Abandoned AU2001289102A1 (en) 2000-09-15 2001-09-17 Topical formulations for delivery of interleukin-11

Country Status (6)

Country Link
US (2) US6540993B1 (en)
EP (1) EP1320358A2 (en)
AR (1) AR031610A1 (en)
AU (1) AU2001289102A1 (en)
TW (1) TWI241192B (en)
WO (1) WO2002022156A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
AU2003296413A1 (en) * 2002-09-16 2004-04-30 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US8034048B2 (en) 2003-05-05 2011-10-11 Boston Scientific Scimed, Inc. Tissue patches and related delivery systems and methods
US7416546B2 (en) * 2003-05-05 2008-08-26 Boston Scientific Scimed, Inc. Tissue patches and related delivery systems and methods
EP1704164B1 (en) * 2003-12-03 2011-12-28 Kröz, Monika Interleukin-11 fusion proteins
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
JP5191393B2 (en) * 2006-10-27 2013-05-08 国立大学法人大阪大学 Use of interleukin 11 as a treatment for heart disease
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
US9931296B2 (en) 2010-04-03 2018-04-03 Praful Doshi Medical devices including medicaments and methods of making and using same
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CA2862290A1 (en) * 2012-01-18 2013-10-17 Neumedicines, Inc. Il-12 for radiation protection and radiation-induced toxicity mitigation
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
AU2020211695A1 (en) 2019-01-21 2021-09-02 National University Of Singapore Treatment of hepatotoxicity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPS60243028A (en) 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd Solubilization of interferon
DE68907066T2 (en) 1988-01-29 1993-12-16 Koken Kk Improved formulations with controlled delivery.
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5215895A (en) 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5371193A (en) 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
DK0546124T4 (en) 1990-08-29 2003-05-19 Inst Genetics Llc Multiple-domain hematopoiesis stimulators
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
BR9205864A (en) 1991-04-08 1994-06-28 Sumitomo Pharma Porous solid formulations containing physiologically active proteinaceous substances.
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5460810A (en) 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543138A (en) 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
EP0684308B2 (en) * 1994-05-27 2004-01-14 Agrano Ag Process for production of a biomass and bread leavening agent
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
NZ516664A (en) 1999-07-15 2003-06-30 Inst Genetics Llc Formulations and compositions for interleukin-11

Also Published As

Publication number Publication date
EP1320358A2 (en) 2003-06-25
WO2002022156A8 (en) 2003-02-20
US20030147849A1 (en) 2003-08-07
AR031610A1 (en) 2003-09-24
WO2002022156A2 (en) 2002-03-21
US6540993B1 (en) 2003-04-01
TWI241192B (en) 2005-10-11
WO2002022156A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001289102A1 (en) Topical formulations for delivery of interleukin-11
AU781269C (en) Pharmaceutical compositions
AU6310000A (en) Aerosol formulations
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2001257326A1 (en) Topical anesthetic/opioid formulations and uses thereof
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2002333644A1 (en) Dry powder medicament formulations
AU2002330273A1 (en) Liposome-encapsulated insulin formulations
AU2001250420A1 (en) Pharmaceutical compositions
AU3192700A (en) Medicinal compositions
AU2001274307A1 (en) Pharmaceutical compositions
AUPQ441699A0 (en) Pour-on formulations
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU5286901A (en) Topical anesthetic formulation
AU2005300A (en) Medicinal compositions
AU2001284444A1 (en) Preparations for oral administration
AU2001267707A1 (en) Antiperspirant formulations
AU4328800A (en) Pharmaceutical formulation
AU2002214324A1 (en) Medicinal compositions
AU4905499A (en) Topical aciclovir formulations
AU2001248943A1 (en) Pharmaceutical curative compound
AU2001290239A1 (en) Medicinal composition
AU6715600A (en) Pharmaceutical formulations
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU2001273919A1 (en) Pharmaceutical compositions